Nevro (NVRO) Delivers 5th Consecutive Earnings Beat; Leerink Partners Raises Price Target to $68
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Nevro Reports Third Quarter 2015 Financial Results
November 9, 2015 4:01 PM ESTREDWOOD CITY, Calif., Nov. 9, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2015.
Third Quarter Highlights:
Achieved revenue of $15.4 million in the third quarter of 2015, an increase of 78% as reported, over the same period of the prior year U.S. revenue of $4.5 million for the third quarter of 2015, the first full quarter of commercial availability... More